Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A study looking at high blood pressure and pazopanib treatment (HYPAZ)
This study was done to find out why some people get high blood pressure when taking the drug pazopanib.
The study was open for people to join between 2011 and 2014. The team published the results in 2021.
More about this trial
Pazopanib is a type of drug called a tyrosine kinase inhibitor (TKI). TKIs block the signals that cancer cells need to divide and grow. Pazopanib blocks several different signals. It can help stop cancer cells forming the blood vessels that they need in order to grow.
Pazopanib can cause a rise in blood pressure. Doctors wanted to find out more about how and why this happens.
The main aims of this study were to find out:
- why some people get raised blood pressure with pazopanib
- how pazopanib affects blood vessels
Summary of results
This study was for people with advanced cancer who were due to have pazopanib. Everyone taking part had pazopanib tablets once a day.
The research team took various measurements before, during and after treatment. These included:
- blood pressure
- blood flow in the forearm
- heart rate (pulse)
- stiffness of arteries
- number and size of blood vessels in the eye
A total of 27 people joined this trial. They had a number of different cancers including kidney cancer, soft tissue sarcoma and melanoma skin cancer.
Blood pressure measurements are made up of 2 numbers. For example, 120 over 80 (written as 120/80). The first number is called the systolic pressure. The second number is called the diastolic pressure.
The results showed that after 12 weeks of pazopanib there was an increase in:
- systolic blood pressure (by an average of 12 points)
- diastolic blood pressure (by an average of 10 points)
- the stiffness of some arteries
- the flow of blood in the forearm
The results also showed there was a decrease in:
- the number and size of very small blood vessels in the eye
- heart rate
We have more information about pazopanib in our Cancer drugs section.
The study team concluded that pazopanib can reduce the number and size of very small blood vessels. This can lead to an increase in blood pressure. It can also decrease heart rate.
The team hope that understanding more about how pazopanib affects blood pressure will lead to better ways of preventing or treating an increase. They suggest more research is done to find out more.
More detailed information
There is more information about this research in the reference below.
Please note, this article is not in plain English. It has been written for healthcare professionals and researchers.
Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition–Induced Hypertension – The HYPAZ trial
Kaisa M. Mäki-Petäjä and others
Hypertension, 2021. Volume 77, number 5.
Where this information comes from
We have based this summary on the information in the article above. This has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Duncan Jodrell
Cambridge Cancer Trials Centre
Cambridge Clinical Trials Unit
Cambridge University Hospitals NHS Foundation Trust
Experimental Cancer Medicine Centre (ECMC)
NIHR Cambridge Biomedical Research Centre
NIHR Clinical Research Facility
NIHR Clinical Research Network: Cancer
University of Cambridge
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040